Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with an SEC-registered public debt offering by Bristol-Myers Squibb Company, consisting of $1.5 billion 0.537% notes due 2023, $1 billion 0.750% notes due 2025, $1 billion 1.125% notes due 2027, $1.25 billion 1.450% notes due 2030, $750 million 2.350% notes due 2040 and $1.5 billion 2.550% notes due 2050. Bristol-Myers Squibb, in connection with its previously announced proposed acquisition of MyoKardia, Inc., intends to use the proceeds of the offering to finance a portion of the aggregate cash consideration to be paid to MyoKardia shareholders and to pay related fees and expenses and to use any remaining proceeds for general corporate purposes.
Headquartered in New York City, Bristol-Myers Squibb Company engages in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Its products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States, Puerto Rico and in six foreign countries.
MyoKardia, based in South San Francisco, California, is a clinical-stage biopharmaceutical company engaged primarily in pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious cardiovascular diseases.
The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associates Joseph S. Payne and Joanna Sedlak. The tax team included partner William A. Curran and associate Rebecca A. Rosen. Counsel Betty Moy Huber and associate Michael Comstock provided environmental advice. The intellectual property and technology team included associates Tilak Koilvaram and S. Dream Montgomery. All members of the Davis Polk team are based in the New York office.